Platelet Compatibility of an Artificial Surface Modified with Functionally Active Heparin

Summary Platelet compatibility after coating an artificial material with functionally active heparin was investigated. Blood was circulated in uncoated or heparin coated PVC tubing. In one hour platelet counts decreased from 155 (113-184) ×109/l to 124 (100-148) ×109/l with uncoated compared to 164 (132-192) ×109/l with heparin coated tubing (intergroup p = 0.02). β-thromboglobulin increased from 116 (80-148) μg/l to 1039 (757-1298) μg/l with uncoated and to 352 (229-638) μg/l with heparin coated tubing (intergroup p = 0.005). Platelet counts and β-thromboglobulin correlated closely with complement activation. Solid-phase enzyme immunoassay demonstrated substantial deposition of CD42a/GPIbIX and CD61/GPIIIa on uncoated, but not on heparin coated tubing (intergroup p <0.0005). Scanning electron microscopy demonstrated activated platelets and aggregates on uncoated in contrast to heparin coated tubing, where scattered, unactivated platelets were found. Changes in P-selectin and microparticles were minor. In conclusion, this heparin surface substantially improved platelet compatibility. Markers of choice for in vitro evaluation were platelet counts, β-thromboglobulin and platelet deposition.

[1]  E. Fosse,et al.  Heparin-coated cardiopulmonary bypass equipment. I. Biocompatibility markers and development of complications in a high-risk population. , 1999, The Journal of thoracic and cardiovascular surgery.

[2]  G. Elgue,et al.  Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. , 1998, Thrombosis research.

[3]  P. Garred,et al.  Immobilized heparin inhibits the increase in leukocyte surface expression of adhesion molecules. , 2008, Artificial organs.

[4]  G. Rocker,et al.  The Systemic Inflammatory Response to Cardiopulmonary Bypass: Pathophysiological, Therapeutic, and Pharmacological Considerations , 1997, Anesthesia and analgesia.

[5]  J. Vincent,et al.  Inflammatory response to cardiopulmonary bypass: mechanisms involved and possible therapeutic strategies. , 1997, Chest.

[6]  F. Braet,et al.  Drying cells for SEM, AFM and TEM by hexamethyldisilazane: a study on hepatic endothelial cells , 1997, Journal of microscopy.

[7]  K. Niwaya,et al.  Changes in platelet, granulocyte, and complement activation during cardiopulmonary bypass using heparin-coated equipment. , 1996, Artificial organs.

[8]  E. Fosse,et al.  Differences in blood activation related to roller/centrifugal pumps and heparin coated/uncoated surfaces in a cardiopulmonary bypass model circuit , 1996, Perfusion.

[9]  K. Robinson,et al.  Heparin coated Palmaz-Schatz™ stents are highly thrombo-resistant: A baboon A-V shunt study , 1996 .

[10]  E. Fosse,et al.  Complement and granulocyte activation in two different types of heparinized extracorporeal circuits. , 1995, The Journal of thoracic and cardiovascular surgery.

[11]  E. Fosse,et al.  Disparity in blood activation by two different heparin-coated cardiopulmonary bypass systems. , 1995, The Annals of thoracic surgery.

[12]  L. Matis,et al.  Blockade of C5a and C5b-9 generation inhibits leukocyte and platelet activation during extracorporeal circulation. , 1995, The Journal of clinical investigation.

[13]  E. Fosse,et al.  A new model for evaluation of biocompatibility: combined determination of neoepitopes in blood and on artificial surfaces demonstrates reduced complement activation by immobilization of heparin. , 1995, Artificial organs.

[14]  H. Wendel,et al.  Heparin-coated oxygenators significantly reduce contact system activation in an in vitro cardiopulmonary bypass model , 1994, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[15]  W. Wagner,et al.  Heparin-coated cardiopulmonary bypass circuits: hemostatic alterations and postoperative blood loss. , 1994, The Annals of thoracic surgery.

[16]  W. van Oeveren,et al.  Heparin coating of an extracorporeal circuit partly improves hemostasis after cardiopulmonary bypass. , 1994, The Journal of thoracic and cardiovascular surgery.

[17]  J. Svennevig,et al.  Complement activation during extracorporeal circulation. In vitro comparison of Duraflo II heparin-coated and uncoated oxygenator circuits. , 1993, The Journal of thoracic and cardiovascular surgery.

[18]  G. Elgue,et al.  On the Mechanism of Coagulation Inhibition on Surfaces with End Point Immobilized Heparin , 1993, Thrombosis and Haemostasis.

[19]  H. Matsuda,et al.  Evaluation of the biocompatibility of a new method for heparin coating of a cardiopulmonary bypass circuit. , 1992, ASAIO journal.

[20]  E. Fosse,et al.  Reduced complement activation with heparin-coated oxygenator and tubings in coronary bypass operations. , 1992, The Journal of thoracic and cardiovascular surgery.

[21]  A. Cheung,et al.  Modulation of complement activation on hemodialysis membranes by immobilized heparin. , 1992, Journal of the American Society of Nephrology : JASN.

[22]  G. Sfakianakis,et al.  Platelet preservation during cardiopulmonary bypass with iloprost and Duraflo-II heparin-coated surfaces. , 1991, ASAIO Transactions.

[23]  R. Bartlett,et al.  Prophylactic administration of tranexamic acid preserves platelet numbers during extracorporeal circulation in rabbits. , 1991, ASAIO transactions.

[24]  V. Videm,et al.  Biocompatibility of extracorporeal circulation. In vitro comparison of heparin-coated and uncoated oxygenator circuits. , 1991, The Journal of thoracic and cardiovascular surgery.

[25]  M. R. Rolfs,et al.  Evaluation of Duraflo II heparin immobilized cardiopulmonary bypass circuits. , 1990, ASAIO transactions.

[26]  P. Sims,et al.  Complement proteins C5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor Va and express prothrombinase activity. , 1988, The Journal of biological chemistry.

[27]  M. Kazatchkine,et al.  Structure-function relationships in the inhibitory effect of heparin on complement activation: independency of the anti-coagulant and anti-complementary sites on the heparin molecule. , 1988, Molecular immunology.

[28]  T. Lea,et al.  Quantification in Enzyme‐Linked Immunosorbent Assay of a C3 Neoepitope Expressed on Activated Human Complement Factor C3 , 1988, Scandinavian journal of immunology.

[29]  R. Larsson,et al.  A new non-thrombogenic surface prepared by selective covalent binding of heparin via a modified reducing terminal residue. , 1983, Biomaterials, medical devices, and artificial organs.